Our Postoperative Adjuvant Immunotherapy and Chemotherapy Experience in Malignant Melanom
Malignant melanoma is a melanocyte-derived tumor with an increasing prevalence that is responsible for 65% of the deaths from skin cancers. Its primary treatment consists of total excision. Postoperative adjuvant therapy is administered to improve the overall and disease-free survival. This study was undertaken to assess the effect of postoperative adjuvant immunotherapy and chemotherapy in patients with malignant melanoma.
This was a prospective, single-arm study. A total of 31 patients meeting the inclusion criteria received high dose adjuvant interferon and/or decarbazine postoperatively. The demographic data, disease stage, surgical procedures, and the overall and disease-free survival during the follow-up period were recorded. Statistical analyses were performed.
Of the study participants 18 (58%) were male and 13 (42%) were female, with a mean age of 52.6 years. The average duration of follow up was 17.58 months. The average overall survival was 11 months and the average disease-free survival was 10 ± 1.6 months.
Postoperative adjuvant immunotherapy was previously reported to improve the disease-free survival in patients with malignant melanoma, and similarly adjuvant immunotherapy + chemotherapy was also found to improve the overall and disease-free survival. Our data represent the interim results of the follow-up, with more data to be collected regarding disease-free and overall survival with further follow-up.